MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

Defining the role of mTOR in cancer

Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833

Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy

Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967

Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition

Sun, S., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 800

Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment

Jura, N., Endres, N., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009) · Cell · doi:10.1016/j.cell.2009.04.025 · Cited by 609

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D. J., Brandhuber, B. J., Gross, S. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodríguez, O., Guzmán, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 541

Cancer modeling in colorectal organoids reveals intrinsic differences between oncogenic RAS and BRAF variantsPreprint

Post, J. B., Hami, N., Lohuis, J. O., van de Ven, M., de Korte‐Grimmerink, R., Stangl, C., Stelloo, E., Verlaan-Klink, I., van Rheenen, J., & Snippert, H. J. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/860122 · Cited by 3

AKT drives sustained motility following MEK inhibition via promoting SNAIL and AXL in MDA-MB-231 LM2

Kwon, J., Helfman, D. M., & Kim, M. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.043 · Cited by 2

Development of a novel PIK3CA-mutated pancreatic tumor mouse model and evaluation of the therapeutic effects of a PI3K inhibitor

Suzuki, Y., Sugimori, M., Kanemaru, Y., Onodera, S., Tsuchiya, H., Ikeda, A., Ikeda, R., Goda, Y., Kaneko, H., Irie, K., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326491 · Cited by 2

KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)

Song, K. W., Ong, C. C., Lin, E., Lau, J., Sodir, N. M., Jin, D. X., Hutchinson, K. E., Xie, S., Tan, J., Liang, Y., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0995 · Cited by 3

Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

Navarro, S., Musulén, E., Cuatrecasas, M., Landolfi, S., y Cajal, S. R., García‐Carbonero, R., García‐Foncillas, J., Pérez‐Segura, P., Salazar, R., & Alfonso, P. G. (2014) · Revista Española de Patología · doi:10.1016/j.patol.2014.09.004 · Cited by 3

mTOR Inhibition Beyond Rapalogs

Markman, B., Serra, V., & Tabernero, J. M. (2015) · Springer eBooks · doi:10.1007/978-2-8178-0492-7_12 · Cited by 2

An Overview of Breast Cancer Therapy

Mahmoud, A. S., Zakaria, Z. A., Hamzah, H. H., & Tengku Ahbrizal, F. T. A. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681089522112010014 · Cited by 2

Signalling pathways drive heterogeneity of ground state pluripotencyPreprint

McEwen, K. R., Linnett, S., Leitch, H. G., Srivastava, P. K., Zouabi, L. A., Huang, T.-C., Rotival, M., Sardini, A., Chan, T. E., Filippi, S., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/373373 · Cited by 2

CASTOR1 : A Novel Tumor Suppressor Linking mTORC1 and KRAS Pathways in Tumorigenesis and Resistance to KRAS-Targeted Therapies in Non-Small Cell Lung CancerPreprint

Wang, X., Ding, L., Sun, S., Loo, S. K., Chen, L., Li, T., Wang, M.-T., Pennathur, A., Huang, Y., & Gao, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.23.650349 · Cited by 2

Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation events

Chen, L., Pruteanu-Malinici, I., Dastur, A., Yin, X., Frederick, D. T., Sadreyev, R. I., & Benes, C. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-86694-5 · Cited by 1

RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Fox, R. G., Kemp, S. B., Juneja, P., Morris, J., Hollingshead, M. G., Takebe, N., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0582 · Cited by 2

Retrospective Study of Trametinib in Patients With Advanced NF1 –Mutant Melanoma

Wang, L., Kashani–Sabet, M., Dighe, P. R., & Kim, K. B. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00984 · Cited by 1

In silico molecular docking and molecular dynamics simulation of Baeckea frutescens phytochemicals as mitogen-activated protein kinase 3 (MAPK3) potential inhibitors

Trang, H. T. T., Giang, N. T. T., Tram, N. T. T., Ha, N. X., & Lê, C. H. (2026) · Journal of Chemical Research · doi:10.1177/17475198261417807 · Cited by 1

Mutant-Selective T-cell Receptor Therapy for Solid Tumors

Parry, S. R., Jang, C., Leal, A., & Punekar, S. R. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0894 · Cited by 1

Furin-like enzyme dependency in KRAS-mutant colorectal cancer as a target for personalized treatment strategies

Siegfried, G., Liu, Y., He, Z., Évrard, S., Badiola, I., Pernot, S., Creemers, J. W. M., & Khatib, A. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189620 · Cited by 1

The Significance of Recognition of Human Epidermal Growth Factor 2 Low in Breast Cancer Therapy

Tozbikian, G. H. (2023) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000408 · Cited by 1

GTP-Competitive Inhibitors of RAS Family Members

Hunter, J. C., Gray, N. S., & Westover, K. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00009-6 · Cited by 1

Oncogenic ALK signaling in neuroblastoma

Umapathy, G. (2017) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1

Targeted phosphoproteomics of the Ras signaling network reveal regulatory mechanisms mediated by oncogenic KRASPreprint

Urisman, A., Yuan, T. L., Trinidad, M. I., Morris, J. H., Afghani, S., Osés-Prieto, J. A., Ritchie, C. D., Zahari, M. S., Benes, C. H., Burlingame, A. L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/695460 · Cited by 1

Elucidating the molecular aspects of colorectal cancer and their clinical importance

Sanz‐García, E., Marino, D., Élez, E., Macarulla, T. M., Capdevila, J., Alsina, M., Argilés, G., Saurí, T., & Tabernero, J. M. (2015) · Colorectal Cancer · doi:10.2217/crc.15.21

Efficacy of organic nanocarriers in a 3D colorectal cancer in vitro model

Davila, V. L. (2015) · UCL Discovery (University College London)

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-Inhibitors

Medizin, E., & Mayr, G. W. (2015)

Age-related effects on the mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in breast cancer and the characterization of novel MEK5 inhibitors

Monlish, D. A. (2013)

MEK inhibition in pancreas cancer

Vena, F. (2016) · UCL Discovery (University College London)

Mechanisms of IKBKE Activation in Cancer

Challa, S. (2017) · Digital Commons - University of South Florida (University of South Florida)

Neoplasia of the Gastrointestinal Tract

Margalit, O., & DuBois, R. N. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch31

Characterising novel phosphatase enzymes important in regulating androgen receptor function in the progression of castrate resistant prostate cancer

Grey, J. (2017)

A novel reporter for real-time, quantitative imaging of AKT-directed K63-poly-ubiquitination in living cells

Nyati, S., Chaudhry, N., Chatur, A., Gregg, B. S., Kimmel, L. E., Khare, D., Basrur, V., Ray, D., & Rehemtulla, A. (2018) · Oncotarget · doi:10.18632/oncotarget.24323

Unravelling Lung Cancer Heterogeneity and Associated Therapeutic Responses using in vivo and ex vivo Model Systems

Nagaraj, A. S. (2018) · Työväentutkimus Vuosikirja

Explorando a quinase IKK como um alvo terapêutico para células iniciadoras de tumor pulmonares induzidas pelo oncogene KRAS

Rodrigues, F. S. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2018.tde-26112018-080111

Role of RAS signaling in Hedgehog-associated embryonal rhabdomyosarcoma

Bauer, J. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7239

Exploration of the role of CIB1 in cell survival and tumor growth

Black, J. L. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/f82n-3148

TARGETING THE ERK MAPK PATHWAY IN RAS-DRIVEN CANCERS

Ryan, M. B. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/jjj1-7f72

Regulation of ERK1/2 signaling in melanoma

Haydn, J. M. (2012)

Glutamine: fructose-6-phosphate aminotransferase 2 (GFPT2) is a novel NF-kB target that links cancer metabolism with metastatic phenotypes in non-small cell lung cancer

Szymura, S. J. (2016) · doi:10.18130/v30p4q

NGF activates NFAT via the MEK1/2 pathway in PC12 cells

Kim, M. S. (2022) · All Life · doi:10.1080/26895293.2022.2034670

Molecular Targetable Pathways – EGFR

Lee, R. E., Jr., Girard, N., & Popat, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00146-3

A Combinatorial Strategy for Tageting Papillary Thyroid Carcinoma with MEK Inhibitor and SHP2 InhibitorPreprint

Zhi, J., Yi, J., Hou, X., Wang, W., Yang, W., Hu, L., Huang, J., Guo, S., Ruan, X., Zheng, X., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-86062/v1

Suppression of Breast Cancer Metastasis Through the Inactivation of ADP-Ribosylation Factor 1

Xie, X., Tang, S., Cai, Y., Pi, W., Deng, L., Wu, G., Chavanieu, A., & Teng, Y. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pacr.1.2020.16

miR-103a-3p suppresses cell proliferation and migration in Hirschsprung’s disease partly by targeting PIK3R1Preprint

Lua, Y., Wangª, C., Yanga, L., Yu, D., Kaisi, F., Zhang, M., Caiyun, L., Huang, Z., Su, Y., Yang, Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2724085/v1

Merged pdf from ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma

Capparelli, C., Purwin, T. J., Heilman, S. A., Chervoneva, I., McCue, P. A., Berger, A. C., Davies, M. A., Gershenwald, J. E., Krepler, C., & Aplin, A. E. (2023) · doi:10.1158/0008-5472.22419945

Merged pdf from ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma

Capparelli, C., Purwin, T. J., Heilman, S. A., Chervoneva, I., McCue, P. A., Berger, A. C., Davies, M. A., Gershenwald, J. E., Krepler, C., & Aplin, A. E. (2023) · doi:10.1158/0008-5472.22419945.v1

Data from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling

Li, D., Miermont, A. M., Sable, R. V., Quadri, H. S., Griner, L. A. M., Martin, S. E., Odzorig, T., De, S., Ferrer, M., Powers, A. S., et al. (2023) · doi:10.1158/1541-7786.c.6534771.v1

Data from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling

Li, D., Miermont, A. M., Sable, R. V., Quadri, H. S., Griner, L. A. M., Martin, S. E., Odzorig, T., De, S., Ferrer, M., Powers, A. S., et al. (2023) · doi:10.1158/1541-7786.c.6534771.v2

Targeted breast cancer treatment: progress and challenges

Kilor, V. A., Dhote, V. V., Sapkal, N. P., & Khan, S. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91763-6.00014-x

KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation.Preprint

Chernoff, J., Budagyan, K., Cannon, A. C., Chatoff, A. G., Snyder, N. W., Kurimchak, A., & Duncan, J. S. (2024) · Research Square · doi:10.21203/rs.3.rs-3931415/v1

Resistance to Endocrine Therapy in Breast Cancer

Demetriou, D., Khanyile, R., Mbita, Z., & Dlamini, Z. (2024) · Springer eBooks · doi:10.1007/978-3-031-52860-6_5

Discovery and development of Krazati (adagrasib/MRTX849), a potent, selective, orally bioavailable, covalent KRASG12C(OFF) inhibitor

Gill, A. L., & Marx, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00017-6

IKZF2-ERBB4 gene fusion leads to ERBB4 overexpression in Anal Squamous Cell Carcinoma but with no benefit for ERBB4 inhibitionPreprint

Richon, S., Anne, S., Julien, L., Adrien, B., Vacher, S., Botty, R. E., Elsy, E. A., Mariani, P., Neuzillet, C., Lièvre, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.28.625910

Polydopamine Nanoparticle-encapsulated Psoralen Promotes Motor Function Recovery from Spinal Cord Compression Through Regulating Phosphatidylinositol 3-kinase/Protein Kinase B Signaling Through miR-140-5p

Deng, J. K., Duan, Z., Deng, H., & Y, L. (2025) · Pharmacognosy Magazine · doi:10.1177/09731296251385791

AKT as a Therapeutic Target in Cancer

Myint, K. N., & Vivanco, I. (2025) · Current topics in microbiology and immunology · doi:10.1007/82_2025_334 · Cited by 1

Additional file 3 of Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer

Lamsal, A., Andersen, S. B., Johansson, I., Vietri, M., Bokil, A. A., Kurganovs, N. J., Rylander, F., Bjørkøy, G., Pettersen, K., & Giambelluca, M. S. (2024) · Figshare · doi:10.6084/m9.figshare.26573386

Additional file 2 of Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer

Lamsal, A., Andersen, S. B., Johansson, I., Vietri, M., Bokil, A. A., Kurganovs, N. J., Rylander, F., Bjørkøy, G., Pettersen, K., & Giambelluca, M. S. (2024) · Figshare · doi:10.6084/m9.figshare.26573383

Additional file 4 of Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer

Lamsal, A., Andersen, S. B., Johansson, I., Vietri, M., Bokil, A. A., Kurganovs, N. J., Rylander, F., Bjørkøy, G., Pettersen, K., & Giambelluca, M. S. (2024) · Figshare · doi:10.6084/m9.figshare.26573389

Temozolomide increases the generation of cell heterogeneity in ERK activity in glioma cells

Begnini, K. R., Marcolin, J. C., Pereira, L. C., de Souza, L. C. P., Kraemer-Mattos, F., Tórgo, D., Machemer, C., Goulart, G. D. S., Silva, A. O., Santos, J. A. F., et al. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02644-2

Chronic activation of p38α in skeletal muscle causes necrotic changes, but also abolishes expression of MK2, MK3, and MKK6 and the muscle recovers

Gilad, N., Darlyuk‐Saadon, I., Mohanam, M. P., & Engelberg, D. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111338

Caractérisation moléculaire et étude des conséquences fonctionnelles des mutations somatiques du gène NF1 dans les carcinomes bronchiques non à petites cellules

Tlemsani, C. (2018) · theses.fr (ABES) · doi:10.70675/8f53e2e3z34d1z4c4bz80cfz5afce9d3ade3

Colorectal cancer cells respond differentially to autophagy induced by tyrosine kinase inhibitors

Louadj, L., Gerotziafas, G., Sabbah, M., & Larsen, A. K. (2026) · Scientific Reports · doi:10.1038/s41598-026-46997-7

MAPK pathway modulation and its implications in KRAS mutant lung adenocarcinoma

Román, S. D. H. (2023) · theses.fr (ABES) · doi:10.70675/8eaccae1ze96bz4279zb69fzaafa5e50c341

Nouveaux mécanismes de régulation de HER2 dans les cancers HER2 positifs : vers de nouvelles approches thérapeutiques

Blasquez, L. (2024) · theses.fr (ABES) · doi:10.70675/9dc6d191z6bdaz47d2z8b04zb00e69ece518

Decreased PP2A expression and activity represent a therapeutic target for plexiform neurofibroma

Yue, M., Wang, Y., Gu, J., Zhang, C., Chen, Y., Gao, A., Choi, K., Wu, Z., Wang, Z., Pundavela, J., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02315-w · Cited by 1

Integrin-linked kinase (ILK) in hematologic malignancies: Bridging molecular mechanisms to therapeutic innovation

Allela, O. Q. B., Shareef, A., Kyada, A., Malathi, H., Maharana, L., Puri, D., Gupta, H., Polatova, D., Sameer, H. N., Yaseen, A., et al. (2026) · Bioimpacts · doi:10.34172/bi.32638

Lack of Chloride Intracellular Channels (CLICs) confers resistance to hypoxia in Drosophila melanogaster via differential regulation of ERK and AKT pathways

Spitnale, S. J., Seeley, S., Oyetunji, I., Lam, A., Sutherland, M. A., Tanda, S., Berryman, M. A., Singh, H., & Rao, S. G. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154146

MEK Inhibitors and Toll-like Receptor Signaling: Implications for Infection and Inflammation

Planz, O. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135666

Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them

Mariano, M. P., Sgarilli, E., Mijnlieff, D., Visuvasam, B., Blesio, A., Digiacomo, G., Cavazzoni, A., Ferracin, M., & Giovannetti, E. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2026.52

Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design

Hamidi, A. A., Moaven, O., Mahmoudian, R. A., & Abbaszadegan, M. R. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00849-2

Caveolin-1 is associated with acquired selumetinib resistance and altered EGFR signaling in colorectal cancer cells

Duong, H., Nguyen, P.-T., Le, V.-T., Ngo, V.-L., Pham, T.-T.-P., Luu, T.-C., Pham, T.-Y.-T., Ngo, T.-P.-O., Nguyen, T.-T.-H., Do, T.-T.-C., et al. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.104085

CASTOR1 functional inactivation drives KRAS -mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression

Wang, X., Ding, L., Meng, W., Byrnes, E., Loo, S. K., Sun, S., Chen, L., Li, T., Wang, M.-T., Pennathur, A., et al. (2026) · Science Advances · doi:10.1126/sciadv.aeb9836

BindingDB Entry 50016411: Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.

BindingDB (2023) · UC San Diego · doi:10.7270/q2tt4vzr

BindingDB Entry 50015760: The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.

BindingDB (2023) · UC San Diego · doi:10.7270/q2dr30fw

BindingDB Entry 50001175: Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).

BindingDB (2020) · UC San Diego · doi:10.7270/q29w0j00

BindingDB Entry 50021256: Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.

BindingDB (2025) · UC San Diego · doi:10.7270/q29g5sfg

Mechanisms of cetuximab resistance in head and neck squamous cell Carcinoma: Focus on the EGFR–ERK pathway

Galiyeva, L., Grušanović, J., Netušil, J., Melichar, V., Klímová, Z., Kolář, M., Plzák, J., Šáchová, J., Kalfeřt, D., & Vomastek, T. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118568

Abstract 5632: MEK inhibition leads to elevated HER3:PI3K in EGFR or HER2 driven cancer through feedback induction of HER1:3 and HER2:3 dimers.

Hoe, N., Mateling, M., Ma, Y., Jin, K., Zhou, J., Kirkland, R. E., Kuy, C., Liu, X., Kim, P., & Singh, S. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-5632

MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK ‐mediated HER 2 phosphorylation at Thr701

Chen, C., Hsia, T., Yeh, M., Chen, T.-H., Chen, Y., Chen, J., Wei, Y., Tu, C., & Huang, W. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12102 · Cited by 65

Abstract 2321: Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS signaling.

Will, M., Toy, W., Yao, Z., Poulikakos, P. I., Rodrik-Outmezguine, V. S., Schneider, C., Paul, J., Baselga, J. M., Liu, N., Rosen, N. X., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-2321

The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor

Won, J., Yang, H. W., Shin, S., Lee, J., Heo, W. D., & Cho, K. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs021 · Cited by 75

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells

Yuen, H., Abramczyk, O., Montgomery, G. W., Chan, K.-K., Huang, Y., Sasazuki, T., Shirasawa, S., Gopesh, S., Chan, K.-W., Fennell, D. A., et al. (2012) · Bioscience Reports · doi:10.1042/bsr20120050 · Cited by 33